Lilly, Novo lock horns in India's obesity drug race

Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market ...

3 Catalysts That Can Start An Eli Lilly Stock Rally

Eli Lilly (LLY) has shown considerable rally potential, with several occurrences of its stock climbing over 30% in less than ...

Abivax: Here's Why Eli Lilly Could Want Its Oral Ulcerative Colitis Therapy

Abivax (ABVX) stock surged on Obefazimod trial success and takeover rumors. Learn if valuation risks now outweigh reward.
Fierce Biotech

Lilly's obesity pill largely maintains weight lost on injectable GLP-1s

Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug ...

Is Eli Lilly a Buy Before 2026?

Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

Did Eli Lilly Just Find the Holy Grail of Weight Loss?

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection ...

Lilly-backed radiopharma startup Aktis seeks U.S. IPO

Aktis Oncology (AKTS), a radio pharma startup backed by pharma giants such as Eli Lilly (LLY) has submitted initial filings ...
Fierce Pharma

'Our work is never over': How Lilly's 2026 Olympics team-ups align with its own mission

As Eli Lilly gears up to support its partnered athletes, Team USA and the Games themselves at the Milano Cortina 2026 Olympic ...

Eli Lilly Scores Another Major Win: Time to Buy?

The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many other drugmakers are hot on its tail, Lilly has consistently demonstrated that, ...